<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651635</url>
  </required_header>
  <id_info>
    <org_study_id>proADM</org_study_id>
    <nct_id>NCT03651635</nct_id>
  </id_info>
  <brief_title>MR-proADM and CT-proET-1 During ICU Treatment</brief_title>
  <acronym>MR-proADM</acronym>
  <official_title>To Assess and Validate the Use of MR-proADM and the CT-proET-1/MR-proADM Ratio as Prognostic Markers During the First 7 Days of ICU Treat-ment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ThermoFisher Scientific Brahms Biomarkers France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot-study will be a prospective, single-centre, observational study including 100
      critically ill patients consecutively admitted to the medical intensive care unit (ICU) of
      the University hospital of Zurich, Switzerland, to assess and validate the use of MR-proADM
      and the CT-proET1/MR-proADM-ratio as prognostic markers in critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot-study will be a prospective, single-centre, observational study including 100
      critically ill patients consecutively admitted to the medical intensive care unit (ICU) of
      the University hospital of Zurich, Switzerland, to assess and validate the use of MR-proADM
      and the CT-proET1/MR-proADM-ratio as prognostic markers in critically ill patients. After
      obtaining informed consent of the patient or approval of a legal representative and meeting
      of the inclusion, as well as missing exclusion criteria the patients will be enrolled.

      At study enrolment patient health status will be assessed by health related diagnosis and the
      Charlson comorbidity index. This information is obtained routinely in every patient in our
      ICU. The Charlson comorbidity index is calculated based on the medical history of the
      patient. The values of MR-proADM and CT-proET-1 will be measured daily over the first 7 days
      of the ICU stay. If a patient is discharged before day 7, no further measurements will be
      performed. The blood samples will be collected together with the routine blood check on
      admission, as well as each morning. Clinical evaluation of the patients will take place each
      morning including the evaluation of the hemodynamics, organ dysfunction, microcirculation and
      the need for vasopressors.

      The severity of illness of the patient will be assessed using the SAPS II score and the SOFA
      score. SAPS-II reflects the physiological status of the patient within the first 24 hours
      (admission severity) and the SOFA score the number of failing organs (respiration,
      coagulation, liver, cardiovascular, CNS, renal). The SAPS-II will be assessed on Visit 3 and
      the SOFA daily using the information obtained during the routine clinical examination and the
      laboratory results of the day. SAPS II and SOFA scores are part of the routine assessment of
      all our patients in the ICU and are used as quality indicators.

      The status of the microcirculation is assessed using clinical signs (mottling score,
      capillary refill time and sublingual microcirculation functional status) and laboratory
      parameters reflecting the degree of tissue oxygen extraction such as SaO2-SvO2 gap, Pv-aCO2
      gap and the arterial lactate concentration. All these parameters are delivered by the blood
      gas analyser located in the ICU from an arterial and a venous blood sample of 1.5 ml each
      drawn via the arterial and central venous line respectively. These catheters and blood
      samples are part of the routine hemo-dynamic monitoring and assessment of the critically ill
      patient in our ICU.

      The patients' survival status will be assessed on day 7 and day 28 after study enrolment. In
      addition, ICU and hospital mortality are recorded. If the patient is still in the hospital on
      day 28, survival data will be taken from the medical record. In the case the patient is
      dismissed from the hospital the study team will contact him by phone call. If he is not
      reachable (documented attempts) the study team will contact his general practitioner. To be
      in line with data protection requirements the patient gives the consent to contact the
      general practitioner in the informed consent form. No other information than the survival
      status will be collected at this stage. Data collection for the study ends 28 (± 3 days) days
      after enrolment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUROCCs) for MR-proADM</measure>
    <time_frame>7 days</time_frame>
    <description>Area under the concentration-time curve (AUROCCs) over 7 days for MR-proADM grouped by SOFA-Score ≥ 7 on day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUROCCs) for the CT-proET-1/MR-proADM-ratio</measure>
    <time_frame>7 days</time_frame>
    <description>Area-under the concentration-time-curve (AUROCCs) over 7 days for the CT-proET-1/MR-proADM-ratio grouped by SOFA-Score ≥ 7 on day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for MR-proADM and microcirculation status</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for MR-proADM and microcirculation status (mottling score, capillary refill time, sublingual microcirculation functional status) on day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for the CT-proET1/MR-proADM-ratio and microcirculation status</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for the CT-proET1/MR-proADM-ratio and microcirculation status (mottling score, capillary refill time, sublingual microcirculation functional status) on day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for MR-proADM and cardiac biomarkers</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for MR-proADM and cardiac biomarkers during the first 7 days of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for the CT-proET1/MR-proADM-ratio and cardiac biomarkers</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for the CT-proET1/MR-proADM-ratio and cardiac biomarkers during the first 7 days of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for MR-proADM and biomarkers of inflammation</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for MR-proADM and biomarkers of inflammation during the first 7 days of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for the CT-proET-1/MR-proADM-ratio and biomarkers of inflammation</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for the CT-proET-1/MR-proADM-ratio and biomarkers of inflammation during the first 7 days of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for MR-proADM and renal dysfunction</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for MR-proADM and renal dysfunction (AKI defined by KDIGO-Classification) on day 7 or ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between area under the concentration-time curve for the CT-proET1/MR-proADM-ratio and renal dysfunction</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between area under the concentration-time curve for the CT-proET1/MR-proADM-ratio and renal dysfunction (AKI defined by KDIGO-Classification) on day 7 or ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission plasma levels of MR-proADM as a predictor of multiorgan dysfunction</measure>
    <time_frame>7 days</time_frame>
    <description>Admission plasma levels of MR-proADM as a predictor of multiorgan dysfunction (SOFA-Score ≥ 7) on day 7 of ICU treatment (ROC-AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission plasma levels of the CT-proET1/MR-proADM-ratio as a predictor of multiorgan dysfunction</measure>
    <time_frame>7 days</time_frame>
    <description>Admission plasma levels of the CT-proET1/MR-proADM-ratio as a predictor of multiorgan dysfunction (SOFA-Score ≥ 7) on day 7 of ICU treatment (ROC-AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUROCCs for MR-proADM during the first 7 days of ICU treatment as predictors of mortality</measure>
    <time_frame>28 days</time_frame>
    <description>AUROCCs for MR-proADM during the first 7 days of ICU treatment as predictors of mortality on day 7, 28 and hospital-mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUROCCs for the MR-proADM/CT-proET-1-ratio during the first 7 days of ICU treatment as predictors of mortality</measure>
    <time_frame>28 days</time_frame>
    <description>AUROCCs for the MR-proADM/CT-proET-1-ratio during the first 7 days of ICU treatment as predictors of mortality on day 7, 28 and hospital-mortality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Phase Biomarkers</condition>
  <condition>Medical ICU Admitted Patients</condition>
  <arm_group>
    <arm_group_label>Medical ICU Patients</arm_group_label>
    <description>All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling for MR-proADM &amp; CT-proET-1</intervention_name>
    <description>Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM &amp; CT-proET-1</description>
    <arm_group_label>Medical ICU Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During the process of the study we will collect at most 8 additional blood samples (3ml
      each). The collection of the blood samples will be paired with routine laboratory checks. All
      other parameters (health related personal data, comorbidities, values of hemodynamic will be
      reviewed from the chart or evaluated in line with routine daily investigations.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to the medical intensive care unit of the University hospital of
        Zurich during the recruitment period
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted to the medical intensive care unit of the University hospital of
             Zurich during the recruitment period

          -  Male and female participants ≥ 18 years

          -  Written informed consent by the participant after information about the research
             project or if the patient is incapable of giving informed consent, a legal
             representative has confirmed the presumed will of the participant (according Art. 15
             KlinV emergency patients)

        Exclusion Criteria:

          -  Inability of the conscious patients to follow the experimental procedure, e.g. because
             of insufficient language skills (German), mental illness, dementia etc.

          -  Pregnancy

          -  Participation in ongoing clinical trials of other departments of the University
             Hospital Zurich
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Maggiorini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Zürich/ University Hospital Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Maggiorini, MD</last_name>
    <phone>0442552204</phone>
    <phone_ext>+41</phone_ext>
    <email>marco.maggiorini@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva-Maria Kleinert</last_name>
    <phone>0442552127</phone>
    <phone_ext>+41</phone_ext>
    <email>evamaria.kleinert@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Medical intensive care unit</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Maggiorini, MD</last_name>
      <phone>0442552204</phone>
      <phone_ext>+41</phone_ext>
      <email>marco.maggiorini@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>España PP, Capelastegui A, Quintana JM, Bilbao A, Diez R, Pascual S, Esteban C, Zalacaín R, Menendez R, Torres A. Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. J Infect. 2010 Feb;60(2):106-13. doi: 10.1016/j.jinf.2009.11.013. Epub 2009 Dec 2. Review.</citation>
    <PMID>19961875</PMID>
  </reference>
  <reference>
    <citation>Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243-50.</citation>
    <PMID>8995086</PMID>
  </reference>
  <reference>
    <citation>Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82.</citation>
    <PMID>12728155</PMID>
  </reference>
  <reference>
    <citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.</citation>
    <PMID>3928249</PMID>
  </reference>
  <reference>
    <citation>Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993 Dec 22-29;270(24):2957-63. Erratum in: JAMA 1994 May 4;271(17):1321.</citation>
    <PMID>8254858</PMID>
  </reference>
  <reference>
    <citation>Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001 Oct 10;286(14):1754-8.</citation>
    <PMID>11594901</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on &quot;sepsis-related problems&quot; of the European Society of Intensive Care Medicine. Crit Care Med. 1998 Nov;26(11):1793-800.</citation>
    <PMID>9824069</PMID>
  </reference>
  <reference>
    <citation>Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15. doi: 10.1186/cc8872. Epub 2010 Feb 9. Review.</citation>
    <PMID>20144219</PMID>
  </reference>
  <reference>
    <citation>Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000 Apr;21(2):138-67. Review.</citation>
    <PMID>10782362</PMID>
  </reference>
  <reference>
    <citation>Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 2001 Nov;22(11):1693-711. Review.</citation>
    <PMID>11754955</PMID>
  </reference>
  <reference>
    <citation>Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005 Oct;51(10):1823-9. Epub 2005 Aug 11.</citation>
    <PMID>16099941</PMID>
  </reference>
  <reference>
    <citation>Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem. 2006 Jun;52(6):1144-51. Epub 2006 Apr 20.</citation>
    <PMID>16627560</PMID>
  </reference>
  <reference>
    <citation>Albrich WC, Dusemund F, Rüegger K, Christ-Crain M, Zimmerli W, Bregenzer T, Irani S, Buergi U, Reutlinger B, Mueller B, Schuetz P. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis. 2011 May 3;11:112. doi: 10.1186/1471-2334-11-112.</citation>
    <PMID>21539743</PMID>
  </reference>
  <reference>
    <citation>Albrich WC, Rüegger K, Dusemund F, Schuetz P, Arici B, Litke A, Blum CA, Bossart R, Regez K, Schild U, Guglielmetti M, Conca A, Schäfer P, Schubert M, de Geest S, Reutlinger B, Irani S, Bürgi U, Huber A, Müller B. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J. 2013 Oct;42(4):1064-75. doi: 10.1183/09031936.00113612. Epub 2013 Jan 24.</citation>
    <PMID>23349444</PMID>
  </reference>
  <reference>
    <citation>Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, de Pablo F, Ferrer M, Menendez R, Torres A. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J. 2012 May;39(5):1144-55. doi: 10.1183/09031936.00080411. Epub 2011 Nov 10.</citation>
    <PMID>22075489</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Müller B. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care. 2006;10(3):R96. Epub 2006 Jun 28.</citation>
    <PMID>16805922</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9(6):R816-24. Epub 2005 Nov 15.</citation>
    <PMID>16356231</PMID>
  </reference>
  <reference>
    <citation>Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, Bargnoux AS, Guiot J, Lefebvre S, Cristol JP, Sebbane M. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med. 2013 Jan;31(1):215-21. doi: 10.1016/j.ajem.2012.07.017. Epub 2012 Sep 20.</citation>
    <PMID>23000327</PMID>
  </reference>
  <reference>
    <citation>Daka B, Olausson J, Larsson CA, Hellgren MI, Råstam L, Jansson PA, Lindblad U. Circulating concentrations of endothelin-1 predict coronary heart disease in women but not in men: a longitudinal observational study in the Vara-Skövde Cohort. BMC Cardiovasc Disord. 2015 Nov 14;15:146. doi: 10.1186/s12872-015-0141-y.</citation>
    <PMID>26573599</PMID>
  </reference>
  <reference>
    <citation>Guignant C, Voirin N, Venet F, Lepape A, Monneret G. Persistent high level of circulating midregional-proadrenomedullin and increased risk of nosocomial infections after septic shock. J Trauma Acute Care Surg. 2012 Jan;72(1):293-6. doi: 10.1097/TA.0b013e31823a0d23.</citation>
    <PMID>22310138</PMID>
  </reference>
  <reference>
    <citation>Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, Delude RL, Rosengart MR, Yealy DM. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009 Sep;136(3):823-831. doi: 10.1378/chest.08-1981. Epub 2009 Apr 10.</citation>
    <PMID>19363212</PMID>
  </reference>
  <reference>
    <citation>Liu D, Xie L, Zhao H, Liu X, Cao J. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2016 May 26;16:232. doi: 10.1186/s12879-016-1566-3. Review.</citation>
    <PMID>27230573</PMID>
  </reference>
  <reference>
    <citation>Lundberg OH, Bergenzaun L, Rydén J, Rosenqvist M, Melander O, Chew MS. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients. Crit Care. 2016 Jun 9;20(1):178. doi: 10.1186/s13054-016-1361-y.</citation>
    <PMID>27282767</PMID>
  </reference>
  <reference>
    <citation>Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Müller B. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium. 2007 Nov-Dec;14(6):345-51.</citation>
    <PMID>18080871</PMID>
  </reference>
  <reference>
    <citation>Schuetz P, Christ-Crain M, Zimmerli W, Mueller B. Repeated measurements of endothelin-1 precursor peptides predict the outcome in community-acquired pneumonia. Intensive Care Med. 2011 Jun;37(6):970-80. doi: 10.1007/s00134-011-2208-2. Epub 2011 Mar 11.</citation>
    <PMID>21394616</PMID>
  </reference>
  <reference>
    <citation>Schuetz P, Stolz D, Mueller B, Morgenthaler NG, Struck J, Mueller C, Bingisser R, Tamm M, Christ-Crain M. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis. 2008 Feb 28;8:22. doi: 10.1186/1471-2334-8-22.</citation>
    <PMID>18304365</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Champion HR, Sacco WJ, Carnazzo AJ, Copes W, Fouty WJ. Trauma score. Crit Care Med. 1981 Sep;9(9):672-6.</citation>
    <PMID>7273818</PMID>
  </reference>
  <reference>
    <citation>Fleming S, Gill P, Jones C, Taylor JA, Van den Bruel A, Heneghan C, Thompson M. Validity and reliability of measurement of capillary refill time in children: a systematic review. Arch Dis Child. 2015 Mar;100(3):239-49. doi: 10.1136/archdischild-2014-307079. Epub 2014 Sep 26. Review.</citation>
    <PMID>25260515</PMID>
  </reference>
  <reference>
    <citation>Ait-Oufella H, Bige N, Boelle PY, Pichereau C, Alves M, Bertinchamp R, Baudel JL, Galbois A, Maury E, Guidet B. Capillary refill time exploration during septic shock. Intensive Care Med. 2014 Jul;40(7):958-64. doi: 10.1007/s00134-014-3326-4. Epub 2014 May 9.</citation>
    <PMID>24811942</PMID>
  </reference>
  <reference>
    <citation>Ait-Oufella H, Lemoinne S, Boelle PY, Galbois A, Baudel JL, Lemant J, Joffre J, Margetis D, Guidet B, Maury E, Offenstadt G. Mottling score predicts survival in septic shock. Intensive Care Med. 2011 May;37(5):801-7. doi: 10.1007/s00134-011-2163-y. Epub 2011 Mar 4.</citation>
    <PMID>21373821</PMID>
  </reference>
  <reference>
    <citation>Coudroy R, Jamet A, Frat JP, Veinstein A, Chatellier D, Goudet V, Cabasson S, Thille AW, Robert R. Incidence and impact of skin mottling over the knee and its duration on outcome in critically ill patients. Intensive Care Med. 2015 Mar;41(3):452-9. doi: 10.1007/s00134-014-3600-5. Epub 2014 Dec 17.</citation>
    <PMID>25516087</PMID>
  </reference>
  <reference>
    <citation>Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010 Feb 6;375(9713):463-74. doi: 10.1016/S0140-6736(09)61879-1. Epub 2010 Jan 25.</citation>
    <PMID>20097417</PMID>
  </reference>
  <reference>
    <citation>Assink-de Jong E, de Lange DW, van Oers JA, Nijsten MW, Twisk JW, Beishuizen A. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients--calculated sample size: 1816 patients. BMC Infect Dis. 2013 Apr 16;13:178. doi: 10.1186/1471-2334-13-178.</citation>
    <PMID>23590389</PMID>
  </reference>
  <reference>
    <citation>Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med. 2005 Mar 15;142(6):451-66. Erratum in: Ann Intern Med. 2005 May 3;142(9):803.</citation>
    <PMID>15767623</PMID>
  </reference>
  <reference>
    <citation>American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416.</citation>
    <PMID>15699079</PMID>
  </reference>
  <reference>
    <citation>De Backer D, Hollenberg S, Boerma C, Goedhart P, Büchele G, Ospina-Tascon G, Dobbe I, Ince C. How to evaluate the microcirculation: report of a round table conference. Crit Care. 2007;11(5):R101.</citation>
    <PMID>17845716</PMID>
  </reference>
  <reference>
    <citation>Pranskunas A, Koopmans M, Koetsier PM, Pilvinis V, Boerma EC. Microcirculatory blood flow as a tool to select ICU patients eligible for fluid therapy. Intensive Care Med. 2013 Apr;39(4):612-9. doi: 10.1007/s00134-012-2793-8. Epub 2012 Dec 20.</citation>
    <PMID>23263029</PMID>
  </reference>
  <reference>
    <citation>Trzeciak S, McCoy JV, Phillip Dellinger R, Arnold RC, Rizzuto M, Abate NL, Shapiro NI, Parrillo JE, Hollenberg SM; Microcirculatory Alterations in Resuscitation and Shock (MARS) investigators. Early increases in microcirculatory perfusion during protocol-directed resuscitation are associated with reduced multi-organ failure at 24 h in patients with sepsis. Intensive Care Med. 2008 Dec;34(12):2210-7. doi: 10.1007/s00134-008-1193-6. Epub 2008 Jul 2.</citation>
    <PMID>18594793</PMID>
  </reference>
  <reference>
    <citation>Hilty MP, Pichler J, Ergin B, Hefti U, Merz TM, Ince C, Maggiorini M. Assessment of endothelial cell function and physiological microcirculatory reserve by video microscopy using a topical acetylcholine and nitroglycerin challenge. Intensive Care Med Exp. 2017 Dec;5(1):26. doi: 10.1186/s40635-017-0139-0. Epub 2017 May 18.</citation>
    <PMID>28523563</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU</keyword>
  <keyword>Biomarkers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

